MD
Highly rated in
16
conditions
Highly rated in
16
conditions
Check Dr. Macarena I. De La Fuente's experience treating your condition:
About Dr. Macarena I. De La Fuente

Macarena De La Fuente is a Neurologist in Miami, Florida. De La Fuente has been practicing medicine for over 18 years and is highly rated in 16 conditions, according to our data. Her top areas of expertise are Glioma, Glioblastoma, Astrocytoma, and Gliomatosis Cerebri. She is licensed to treat patients in New York. De La Fuente is currently accepting new patients.

Her clinical research consists of co-authoring 27 peer reviewed articles and participating in 10 clinical trials in the past 15 years.

Insurance

MediFind strives to display the most accurate insurance information for every doctor. If you do not see your insurance listed for Dr. Macarena I. De La Fuente it is best to call her office and ask if your insurance is accepted.

Accepts Medicare

Dr. Macarena I. De La Fuente accepts the following insurance:

  •  Ambetter
  •  Bright Health
  •  Molina Healthcare
  •  Oscar
  •  UnitedHealthcare
  •  Sunshine Health
View 2 More Insurances +
Locations
1475 Nw 12th Ave, Miami, FL 33136
Other Locations
1120 Nw 14th St, Miami, FL 33136
Background & Education
Graduate Institution
Other, 2004
Specialties
Neurology
Licenses
Psychiatry & Neurology in NY
Hospital Affiliations
Sylvester Comprehensive Cancer Center
Cleveland Clinic Martin North Hospital
UHealth Tower
Languages Spoken
English
Spanish
Gender
Female
Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Doctors who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.


10 Clinical Trials

Phase II Trial of BRAF/MEK Inhibitors in Papillary Craniopharyngiomas
A Phase 1/2 Study of PBI-200 in Subjects With NTRK-Fusion-Positive Advanced or Metastatic Solid Tumors
GBM AGILE: Global Adaptive Trial Master Protocol: An International, Seamless Phase II/III Response Adaptive Randomization Platform Trial Designed To Evaluate Multiple Regimens In Newly Diagnosed and Recurrent GBM
A Phase 2 Study of the PARP Inhibitor Olaparib (AZD2281) in IDH1 and IDH2 Mutant Advanced Solid Tumors
Phase II Trial of SMO/ AKT/ NF2/CDK Inhibitors in Progressive Meningiomas With SMO/ AKT/ NF2/CDK Pathway Mutations
Pilot Study for Non-invasive Glioma Characterization Through Molecular Imaging
Dendritic Cell Vaccine For Malignant Glioma and Glioblastoma Multiforme in Adult and Pediatric Subjects
Pilot Study of Optune (NovoTTF-100A) for Recurrent Atypical and Anaplastic Meningioma
An Open-Label, Multi-Center Trial of INO-5401 and INO-9012 Delivered by Electroporation (EP) in Combination With REGN2810 in Subjects With Newly-Diagnosed Glioblastoma (GBM)
A Phase II/III Randomized Trial of Veliparib or Placebo in Combination With Adjuvant Temozolomide in Newly Diagnosed Glioblastoma With MGMT Promoter Hypermethylation
View 4 Less Clinical Trials -

Save this doctor for later
Sign Up
Looking for the best doctor for you?
Start Here
Is this your doctor?
Find a second opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn more
Similar Doctors